How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement

被引：2

作者：

Naoe, Tomoki ^{[1
]}

机构：

[1] Natl Hosp Org Nagoya Med Ctr, Nagoya, Aichi, Japan

来源：

NAGOYA JOURNAL OF MEDICAL SCIENCE | 2020年 / 82卷 / 02期

关键词：

elderly patients; acute myeloid leukemia; chemotherapy; molecule-targeted drug; prognosis; ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; LOW-DOSE CYTARABINE; CONVENTIONAL CARE REGIMENS; OLDER PATIENTS; ARSENIC TRIOXIDE; PLUS CYTARABINE; PHASE-2; TRIAL; OPEN-LABEL; AML;

D O I：

10.18999/nagjms.82.2.151

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Among elderly patients with acute myeloid leukemia (AML), especially those who are unfit for intensive chemotherapy, a policy of reduced-intensity chemotherapy or conservative observation has been chosen, resulting in unmet medical needs. Clinical trials using anticancer drugs including antimetabolites or drugs targeted to cell cycle-related molecules failed to show superiority over conventional treatments. Recently, drugs targeted to Bcl-2, SMO, FLT3, and IDH1/2 have been shown to prolong overall survival alone or in combination with reduced-intensity chemotherapy. These treatments are likely to reshape the therapeutic landscape of AML, which will be personalized for individual patients based on leukemia genetics.

引用

页码：151 / 160

页数：10

共 56 条

[51]

Swerdlow SH, 2017, WHO CLASSIFICATION T

[52] Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment [J].